Optimal Care for Kidney Health : Development of a Merit-based Incentive Payment System (MIPS) Value Pathway
Copyright © 2023 by the American Society of Nephrology..
The Merit-based Incentive Payment System (MIPS) is a mandatory pay-for-performance program through the Centers for Medicare & Medicaid Services (CMS) that aims to incentivize high-quality care, promote continuous improvement, facilitate electronic exchange of information, and lower health care costs. Previous research has highlighted several limitations of the MIPS program in assessing nephrology care delivery, including administrative complexity, limited relevance to nephrology care, and inability to compare performance across nephrology practices, emphasizing the need for a more valid and meaningful quality assessment program. This article details the iterative consensus-building process used by the American Society of Nephrology Quality Committee from May 2020 to July 2022 to develop the Optimal Care for Kidney Health MIPS Value Pathway (MVP). Two rounds of ranked-choice voting among Quality Committee members were used to select among nine quality metrics, 43 improvement activities, and three cost measures considered for inclusion in the MVP. Measure selection was iteratively refined in collaboration with the CMS MVP Development Team, and new MIPS measures were submitted through CMS's Measures Under Consideration process. The Optimal Care for Kidney Health MVP was published in the 2023 Medicare Physician Fee Schedule Final Rule and includes measures related to angiotensin-converting enzyme inhibitor and angiotensin receptor blocker use, hypertension control, readmissions, acute kidney injury requiring dialysis, and advance care planning. The nephrology MVP aims to streamline measure selection in MIPS and serves as a case study of collaborative policymaking between a subspecialty professional organization and national regulatory agencies.
| Errataetall: |
CommentIn: J Am Soc Nephrol. 2023 Aug 1;34(8):1297-1299. - PMID 37526982 |
|---|---|
| Medienart: |
E-Artikel |
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:34 |
|---|---|
| Enthalten in: |
Journal of the American Society of Nephrology : JASN - 34(2023), 8 vom: 01. Aug., Seite 1315-1328 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Tummalapalli, Sri Lekha [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
|---|
| Anmerkungen: |
Date Completed 02.08.2023 Date Revised 07.09.2023 published: Print-Electronic CommentIn: J Am Soc Nephrol. 2023 Aug 1;34(8):1297-1299. - PMID 37526982 Citation Status MEDLINE |
|---|
| doi: |
10.1681/ASN.0000000000000163 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM359013023 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM359013023 | ||
| 003 | DE-627 | ||
| 005 | 20231226075947.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1681/ASN.0000000000000163 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1196.xml |
| 035 | |a (DE-627)NLM359013023 | ||
| 035 | |a (NLM)37400103 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Tummalapalli, Sri Lekha |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Optimal Care for Kidney Health |b Development of a Merit-based Incentive Payment System (MIPS) Value Pathway |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 02.08.2023 | ||
| 500 | |a Date Revised 07.09.2023 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a CommentIn: J Am Soc Nephrol. 2023 Aug 1;34(8):1297-1299. - PMID 37526982 | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Copyright © 2023 by the American Society of Nephrology. | ||
| 520 | |a The Merit-based Incentive Payment System (MIPS) is a mandatory pay-for-performance program through the Centers for Medicare & Medicaid Services (CMS) that aims to incentivize high-quality care, promote continuous improvement, facilitate electronic exchange of information, and lower health care costs. Previous research has highlighted several limitations of the MIPS program in assessing nephrology care delivery, including administrative complexity, limited relevance to nephrology care, and inability to compare performance across nephrology practices, emphasizing the need for a more valid and meaningful quality assessment program. This article details the iterative consensus-building process used by the American Society of Nephrology Quality Committee from May 2020 to July 2022 to develop the Optimal Care for Kidney Health MIPS Value Pathway (MVP). Two rounds of ranked-choice voting among Quality Committee members were used to select among nine quality metrics, 43 improvement activities, and three cost measures considered for inclusion in the MVP. Measure selection was iteratively refined in collaboration with the CMS MVP Development Team, and new MIPS measures were submitted through CMS's Measures Under Consideration process. The Optimal Care for Kidney Health MVP was published in the 2023 Medicare Physician Fee Schedule Final Rule and includes measures related to angiotensin-converting enzyme inhibitor and angiotensin receptor blocker use, hypertension control, readmissions, acute kidney injury requiring dialysis, and advance care planning. The nephrology MVP aims to streamline measure selection in MIPS and serves as a case study of collaborative policymaking between a subspecialty professional organization and national regulatory agencies | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Research Support, U.S. Gov't, P.H.S. | |
| 700 | 1 | |a Struthers, Sarah A |e verfasserin |4 aut | |
| 700 | 1 | |a White, David L |e verfasserin |4 aut | |
| 700 | 1 | |a Beckrich, Amy |e verfasserin |4 aut | |
| 700 | 1 | |a Brahmbhatt, Yasmin |e verfasserin |4 aut | |
| 700 | 1 | |a Erickson, Kevin F |e verfasserin |4 aut | |
| 700 | 1 | |a Garimella, Pranav S |e verfasserin |4 aut | |
| 700 | 1 | |a Gould, Edward R |e verfasserin |4 aut | |
| 700 | 1 | |a Gupta, Nupur |e verfasserin |4 aut | |
| 700 | 1 | |a Lentine, Krista L |e verfasserin |4 aut | |
| 700 | 1 | |a Lew, Susie Q |e verfasserin |4 aut | |
| 700 | 1 | |a Liu, Frank |e verfasserin |4 aut | |
| 700 | 1 | |a Mohan, Sumit |e verfasserin |4 aut | |
| 700 | 1 | |a Somers, Michael |e verfasserin |4 aut | |
| 700 | 1 | |a Weiner, Daniel E |e verfasserin |4 aut | |
| 700 | 1 | |a Bieber, Scott D |e verfasserin |4 aut | |
| 700 | 1 | |a Mendu, Mallika L |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Journal of the American Society of Nephrology : JASN |d 1990 |g 34(2023), 8 vom: 01. Aug., Seite 1315-1328 |w (DE-627)NLM012606502 |x 1533-3450 |7 nnns |
| 773 | 1 | 8 | |g volume:34 |g year:2023 |g number:8 |g day:01 |g month:08 |g pages:1315-1328 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1681/ASN.0000000000000163 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 34 |j 2023 |e 8 |b 01 |c 08 |h 1315-1328 | ||